Skip to main content

Table 2 Feasibility, clinical efficacy and patient centred outcomes

From: A randomised feasibility study of serial magnetic resonance imaging to reduce treatment times in Charcot neuroarthropathy in people with diabetes (CADOM): a protocol

Feasibility outcomesClinical efficacy outcomes (collected at all study visit)Patient centred outcomes (collected at baseline, 3 monthly until remission, then at 1 and 6 months post remission)
The proportion of patients who meet the eligibility criteriaNumber of new ulcerations on the index or contralateral footHealth-related quality of life measured:
Short Form 12 questionnaire (SF-12) [40]
EuroQol-5D-5 L questionnaire (EQ-5D-5 L) [41]
The number of eligible patients recruitedNumber of new infections on the index or contralateral footHospital Anxiety and Depression Scale (HADS) [42]
The number of participants in which an alternative diagnosis is made during the active phase of the trialNumber of minor and major amputations on the index or contralateral foot at the end of the follow-up phase of the studyPain as assessed by Visual Analogue Scale (VAS)
The proportion of patients that withdraw or are lost to follow-up. The term ‘withdrawal’ encompasses two potential scenarios: withdrawal due to loss of consent or withdrawal due to deathsNumber and severity of falls (Hopkins Fall Grading System) [43]Patient diary
Statistical parameters of the key outcome measures, duration in off-loading  to inform a sample size calculation for a definitive trialThe number of participants in each arm requiring further intervention for CN (e.g. further immobilisation) within 6 months of remission 
Ability to collect quality of life and resource use data